AR and prostate cancer: Via a non-canonical pathway, EZH2 methylates and activates STAT3 (Signal Transducer And Activator Of Transcription 3), acts as a co-activator for androgen receptor (AR) in castration resistant prostate cancer and enhances cellular proliferation via the E2F pathway (reviewed in [12]).